FlandersBio on Twitter

Follow us on Twitter

new technology - News

new technology - Nieuws

in het nederlands in english

FlandersBio informs you about important regional and national life sciences news. Send us your news. If your news is of interest to the life sciences community, we will post it on our website.

FlandersBio informeert u over belangrijk nieuws op het vlak van de biowetenschappen. Bezorg ons jouw nieuwtjes. Als het interessant is voor de sector, zullen wij het op onze website plaatsen.

Galapagos licenses Organoid Technology from the HUB foundation for use in cystic fibrosis and IBD research

15.07.2015

Galapagos NV (Euronext & NASDAQ: GLPG) announced today that it has entered into a licensing agreement with the HUB foundation for use of Organoid Technology for pre-clinical research in cystic fibrosis (CF) and inflammatory bowel disease (IBD). read more

FLUIDDA, DE MEDTECH KROONJUWEEL, OPENT DEUREN VOOR OPRICHTING MEDTECH FLANDERS

29.06.2015

FLUIDDA, één van de parels van de Vlaamse medische spitstechnologie, is op 29 juni de gastheer voor de oprichting van MedTech Flanders, de cluster van Vlaamse medtech-organisaties. FLUIDDA’s innovatieve beeldtechnologie en het nieuwe BRONCHOLABTM geven een unieke 3D-inkijk in de longen. De analyses helpen nieuwe geneesmiddelen sneller naar de markt en laten toe betere aerosoltoestellen te ontwikkelen. read more

Biogazelle offers unique microRNA sequencing on challenging samples

12.06.2015

Biogazelle has a longstanding track record and internationally recognized expertise in RNA gene expression analysis, with a particular focus on non-coding RNA, such as microRNAs and long non-coding RNAs. Today, the service portfolio is extended with a unique offering, namely the use of massively parallel sequencing to quantify microRNAs in compromised samples characterized by degraded RNA or low output amounts of RNA. read more

ABLYNX PRESENTS UNIQUE NANOBODY DRUG INHALATION TECHNOLOGY AT THE RESPIRATORY DRUG DELIVERY EUROPE 2015 CONFERENCE

07.05.2015

Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] presented an overview of its unique and versatile Nanobody platform and its application for inhaled biological medication at the Respiratory Drug Delivery (RDD) Europe 2015 Conference (Nice, France, May 5-8). read more

arGEN-X Launches Innovative Access Program

12.01.2015

arGEN-X N.V. (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, today announced it has initiated its Innovative Access Program, providing its SIMPLE Antibody™ platform to academic centers of excellence and emerging biotech companies through collaboration. The goal of this program is to exploit the proven power of the SIMPLE Antibody™ platform in therapeutic areas complementary to arGEN-X’s strategic focus. read more

Esperite 's R&D Division "The Cell Factory" implements GMP Stem Cell Bioproduction Technology and aims the Cerebral Palsy as first clinical trial

26.09.2014

Esperite (Euronext.: ESP), the European leader in stem cells cryopreservation now entering the fields of predictive medicine and translational regenerative medicine R&D,, implements its own proprietary new technology for clinical grade production of autologous mesenchymal and stromal stem cells in its business unit The Cell Factory. read more

Apitope Treatment Approach Published in Nature Communications

08.09.2014

Apitope, the drug discovery and development company focused on disease-modifying treatments for patients with autoimmune and allergic diseases, announced today that Bristol University research led by Apitope Founder and CSO, Prof David Wraith, on its treatment approach to autoimmune diseases, such as Multiple Sclerosis (MS), has been published in Nature Communications. read more

New technology for the detection of genetic abnormalities which lead to serious epilepsy

22.01.2014

A European consortium of epilepsy researchers has reported the discovery of a new gene involved in severe childhood epilepsy. Using a novel combination of technologies, including trio exome sequencing of patient/parental DNA and genetic studies in the tiny larvae of zebrafish, the EuroEPINOMICS RES consortium found that mutations in the gene CHD2 are responsible for a subset of epilepsy patients with symptoms similar to Dravet syndrome – a severe form of childhood epilepsy that is in many patients resistant to currently available anti-epileptic drugs. The discovery of CHD2’s role in epilepsy offers new diagnostic tools for families and clinicians of children with Dravet syndrome and related genetic epilepsies. In addition, the creation of a zebrafish model for CHD2 encephalopathy may facilitate the discovery of new drugs that can treat patients with this form of epilepsy. read more

FLUIDDA PRESENTS NOVEL IMAGING TECHNOLOGY FOR RESPIRATORY DISEASES TO FDA

18.12.2013

FLUIDDA develops proprietary Functional Respiratory Imaging (FRI) technology that provides a unique entry point into personalized medicine for respiratory diseases. FRI reduces significantly the number of patients needed in clinical trials, resulting in better drugs coming to the market faster. FLUIDDA is invited by the FDA to present the benefits of this unique technology for the screening of new respiratory drugs. read more

Gentse en Leuvense bio-ethici ontketenen mediastorm door onthulling van Amerikaans patent op methode om designer babies te ontwikkelen

04.10.2013

Bio-ethici van de UGent en de KU Leuven becommentariëren deze week in Genetics in Medicine (Nature) het controversiële patent dat het bedrijf 23andMe vorige week kreeg voor een methode om zogenaamde designer babies te ontwikkelen. Het bedrijf zou toekomstige ouders de mogelijkheid bieden om bijvoorbeeld de kleur van de ogen, de huidskleur en persoonlijkheidskenmerken van hun kind te kiezen. Het artikel gaf aanleiding tot een internationale mediastorm en wordt becommentarieerd in o.m. Science, The Wall Street Journal, Time magazine, The Independent, MIT Technology Review... en vele andere media. read more

Join E-news

Interested in a regular update of the life sciences and biotech sector in Flanders? Subscribe to our newsletter.

Subscribe now

Back to top

Print